pro-inflammatory cytokine – Page 7 – Communicable Diseases Research

A New Butyrate Releaser Exerts a Protective Action against SARS-CoV-2 Infection in Human Intestine

새로운 부티레이트 방출제는 인간의 장에서 SARS-CoV-2 감염에 대한 보호 조치를 취합니다

Article

Published on 2022-01-272022-09-10
Journal: Molecules [Category] SARS, 유전자 메커니즘, 치료제,

A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection

사전 융합 안정화 SARS-CoV-2 스파이크 단백질을 발현하는 MVA 백신의 단일 용량은 우려의 변종을 중화하고 치명적인 SARS-CoV-2 감염으로부터 마우스를 보호합니다

Immunology

Published on 2022-01-272022-09-11
Journal: Frontiers in Immunology [Category] 변종, 진단,

[키워드] administration animal models Antibody titers C57BL/6 caused Cell clinical trials concern COVID-19 vaccine Cytokines demonstrated dose Efficacy expressed expressing expression full-length hACE2 histopathological IgG immune responses immunized immunogenicity K18-hACE2 mice lesions lethal Lungs mice modified vaccinia virus morbidity morbidity and mortality mouse model MVA vector Neutralizing antibody titer neutralizing antibody titers parental poxvirus prefusion-stabilized S protein pro-inflammatory cytokine pro-inflammatory cytokines protective efficacy Protein reducing S protein SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 S protein SARS-CoV-2 spike SARS-CoV-2 vaccine SARS-CoV-2 viral loads single dose spike T-cell immune responses transgenic vaccine candidate variants variants of concern Viral viral loads viruses wild-type
[DOI] 10.3389/fimmu.2021.824728 PMC 바로가기 [Article Type] Immunology

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs

PDE4 억제제인 Tanimilast는 SARS-CoV-2 ssRNA에 의한 전염증성 수지상 세포 활성화를 둔화시킵니다

Immunology

Published on 2022-01-242022-09-11
Journal: Frontiers in Immunology [Category] 치료법,

[키워드] acquisition activate activated DCs Activation anti-inflammatory drug approved atopic dermatitis blocked CCL3 CCR7 CD4 CD8 CD83 CD86 cDCs chemokine chemokines CHF6001 clinical development Clinical studies COPD COVID-19 CXCL10 CXCL9 cytokine Cytokines DCs demonstrated dendritic cell did not reduce disease dysregulation genomic homing receptor hyperinflammation IL-12 IL-6 immune dysregulation immune response immunomodulatory immunomodulatory drug immunomodulatory drugs impair Inflammatory inflammatory conditions Inhaled inhibitor International Lymph node lymph node homing marker maturation MHC-I MHC-II modulate non-proprietary name pDCs phenotype phosphodiesterase phosphodiesterase 4 (PDE4) inhibitors pro-inflammatory pro-inflammatory cytokine pro-inflammatory cytokines proinflammatory cytokines proliferation psoriasis receptor SARS-CoV-2 SARS-COV-2 infection scenario selective skewed ssRNA steroid T cell T cells Tanimilast Th2 TNF-α treat Treatment type I IFNs
[DOI] 10.3389/fimmu.2021.797390 PMC 바로가기 [Article Type] Immunology

What’s happening where when SARS-CoV-2 infects: are TLR7 and MAFB sufficient to explain patient vulnerability?

Review

Published on 2022-01-222022-10-30
Journal: Immunity & Ageing : I & A [Category] COVID-19,

SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB

SARS-CoV-2 감염은 cGAS-STING 및 NF-κB를 통해 전염증성 사이토카인 반응을 유도합니다

Article

Published on 2022-01-122022-09-10
Journal: Communications Biology [Category] 치료기술, 치료제,

[키워드] Activation antiviral responses block building Cell cGAS complications contribute cytokine cytokine secretion profile Cytokines death detect develop drugs epithelial cells evaluate evaluated global pandemic human epithelial cell human epithelial cells individual induce infected cell culture infected patients infections Inflammatory cytokine Inflammatory cytokines inflammatory immune response Inflammatory response Inflammatory responses IRF3 lead leads long-lasting lung damage majority Mild Mild disease NF-κB nuclear translocation Patient patient sera pro-inflammatory cytokine pro-inflammatory cytokines proportion SARS-CoV-2 SARS-CoV-2 infected cells SARS-COV-2 infection Severe case severe disease severe symptom severe symptoms Spread STING suppress Symptoms therapy transcriptional upregulation viral pathogenesis virus
[DOI] 10.1038/s42003-021-02983-5 PMC 바로가기 [Article Type] Article

The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome

Pharmacology

Published on 2022-01-122022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology

가용성 CD24를 사용한 치료는 COVID-19 관련 전신 면역병리를 약화시킵니다

Clinical Trial

Published on 2022-01-102022-09-12
Journal: Journal of Hematology & Oncology [Category] 임상, 진단,

[키워드] acute respiratory syndrome coronavirus Analysis anti-inflammatory agent anti-inflammatory agents Anti-viral Antibody Response approach attenuate binding blunt cause CD24 CD24Fc CD4 CD56 CD8 cellular compartments chemokine chemokines Clinical characteristics Clinical efficacy coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 severity cytokine Cytokine score Cytokines damage damage-associated molecular pattern Damage-associated molecular patterns demonstrated downstream enrolled epithelial cells Extracellular flow cytometry heat shock proteins homeostasis homology Immune homeostasis immunopathology Immunophenotyping induce infected individuals Inflammatory response Lung epithelial cells Natural killer cells Pathogenesis pathway Patient patients with COVID-19 performed Peripheral blood peripheral blood samples phosphatase placebo group pro-inflammatory cytokine Protein Randomized Release respiratory Result return SARS-CoV-2 SARS-CoV-2-infected individuals severe acute respiratory syndrome coronavirus 2 severe COVID-19 severity shown Siglec10 significantly Soluble CD24 supplementary material systemic cytokine response systemic inflammation T cell T cells therapeutic therapeutic efficacy Treatment Trial with COVID-19
[DOI] 10.1186/s13045-021-01222-y PMC 바로가기 [Article Type] Clinical Trial

Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain: New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19

Review

Published on 2022-01-052022-10-28
Journal: Biomolecules [Category] COVID-19, SARS,

[키워드] ACE2 ACE2 shedding acute respiratory syndrome ADAM17 aggravate airway epithelia all-cause mortality angiotensin-converting enzyme 2 application Betacoronavirus calcium Calcium signaling calmodulin catalytic clinical coronavirus COVID-19 COVID-19 thromboembolic events down-regulation ectodomain Endothelial dysfunction endotoxin entry receptor Evidence form Infection Inflammation inhibit SARS-CoV-2 insight involved Lung injury mechanism membrane metalloproteinase Mortality Neuropilin-1 New pathological change pathway plasma activity pro-inflammatory cytokine Prognosis Protein renin-angiotensin system reported resulting SARS-CoV-2 shedding shown soluble ACE2 soluble catalytic ectodomain of ACE2 Support therapeutic thrombotic TNFα transmembrane Treatment tumor necrosis factor-alpha type I viral entry Vitamin D
[DOI] 10.3390/biom12010076 PMC 바로가기 [Article Type] Review

Analysis of serum cytokine and protective vitamin D levels in severe cases of COVID-19

Article

Published on 2022-01-012022-11-16
Journal: Journal of medical virology [Category] Fulltext, MERS, 치료기술,

[키워드] anti-inflammatory effect Concentration Control control group control groups correlation COVID-19 COVID-19 group COVID-19 patient cytokine cytokine levels cytokine profile Cytokines storm demonstrated enzyme-linked immunosorbent assays Evidence IL-1 IL-10 IL-21 IL-6 illnesses individual Infection intensive care investigated Level liquid Patient patients pro-inflammatory pro-inflammatory cytokine pro-inflammatory cytokines Protective protective effect risk SARS-CoV-2 serum serum cytokine serum cytokine level Serum level serum vitamin D Severe case significantly significantly higher TNF-α tumor necrosis factor-α two groups virus Vitamin D vitamin D level were measured were used
[DOI] 10.1002/jmv.27294 PMC 바로가기

Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice

NLRP3 인플라마좀의 특정 억제는 면역 과잉 활성화를 억제하고 생쥐의 병리와 같은 COVID-19를 완화합니다

Article

Published on 2021-12-312022-09-11
Journal: EBioMedicine [Category] SARS, 유전자 메커니즘, 진단,

[키워드] activated Activation advance alleviate biosafety level BSL-3 Bureau C57BL/6 CAS Cell culture cell cultures conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 disease COVID-19 severity Cytokines education Evidence finding funding global public health histological host gene Host immune response human ACE2 immune immunofluorescence analysis immunopathology indicated inhibition inhibitor injected Intervention intranasally intraperitoneally Invasion involved knockout mice Laboratory level 3 live SARS-CoV-2 Lung inflammation lung tissue lung tissues Lungs macrophages MCC950 mice NLRP3 NLRP3 inflammasome pandemic pathology performed pro-inflammatory cytokine pro-inflammatory cytokines Program provided quantitative real-time PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2, NLRP3 inflammasome, Immune overactivation, Cytokine storm Science severe COVID-19 disease severe COVID-19 patient severe COVID-19 patients severe pathology severity Specific supported suppresse targeting THP-1 tissues transgenic mice Vaccine development Viral was reduced West wild-type with COVID-19
[DOI] 10.1016/j.ebiom.2021.103803 PMC 바로가기 [Article Type] Article